{
    "clinical_study": {
        "@rank": "25235", 
        "arm_group": [
            {
                "arm_group_label": "GS-5806", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single dose of GS-5806."
            }, 
            {
                "arm_group_label": "Placebo to match GS-5806", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive a single dose of placebo to match GS-5806."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the antiviral effect, pharmacokinetics, safety, and tolerability\n      of GS-5806 in respiratory syncytial virus (RSV) positive adults who have been hospitalized\n      with acute respiratory infectious symptoms.\n\n      Participants will be stratified by presence or absence of chronic airways diseases;\n      participants with chronic airways diseases will be further stratified by chronic obstructive\n      pulmonary disease (COPD), asthma, or other. Participants will receive 1 dose of GS-5806 and\n      followed for 28 days postdose. Nasal swabs will be collected at each study visit (excluding\n      Day 28) and assayed for change in viral load as the primary endpoint."
        }, 
        "brief_title": "Study of the Efficacy, Pharmacokinetics, and Safety of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Syncytial Virus (RSV) Infections", 
        "condition_browse": {
            "mesh_term": "Virus Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Admission to the hospital primarily for a respiratory related illness\n\n          -  New onset or acute worsening of at least 1 respiratory infectious symptom from each\n             category with a duration of  \u2264 5 days prior to screening:\n\n               -  Upper respiratory tract symptoms: nasal congestion, runny nose, sore throat, or\n                  earache\n\n               -  Lower respiratory tract symptoms: cough, sputum production, wheezing, dyspnea,\n                  or chest tightness\n\n          -  Documented to be RSV-positive at the current admission within 72 hours of screening,\n             or as evaluated at Screening\n\n        Exclusion Criteria:\n\n          -  Related to medical history:\n\n               -  Pregnant, breastfeeding, or lactating females\n\n               -  Subjects requiring > 50% supplemental oxygen (while the subject is awake) at\n                  Screening\n\n               -  Subjects with a Clinical Frailty Scale (CFS) > 7 at Baseline\n\n               -  Any clinically significant history of a bleeding disorder (as determined by the\n                  investigator) at any time in the past or epistaxis (as determined by the\n                  investigator) within 30 days prior to screening\n\n               -  Known significant abnormality altering the anatomy of the nose or nasopharynx\n                  that in, the opinion of the investigator, will preclude obtaining adequate nasal\n                  swab sampling in either nasal passage\n\n               -  Waiting for or recently (within the past 12 months) received a bone marrow, stem\n                  cell, or solid organ transplant, or who have received radiation or chemotherapy\n                  within 12 months prior to screening\n\n               -  Known history of HIV/AIDS, hepatitis B or C\n\n               -  History of severe dementia or Alzheimer's disease\n\n               -  History of drug and/or alcohol abuse that, in the opinion of the investigator,\n                  may prevent adherence to study activities\n\n          -  Related to medical condition at screening:\n\n               -  Influenza-positive as determined by local diagnostic test\n\n               -  New onset of arrhythmia during current admission\n\n               -  Use of mechanical ventilation during the current admission, not including\n                  noninvasive ventilation\n\n               -  Positive bacteremia or fungemia at the current admission\n\n               -  Inadequate treatment of confirmed bacterial, fungal, or non-RSV pneumonia, as\n                  determined by the investigator\n\n               -  New cerebrovascular accident or stroke documented at the current admission\n\n               -  Admission for trauma or emergent or planned surgeries\n\n               -  Excessive nausea/vomiting at admission, as determined by the investigator, that\n                  precludes administration of an orally administered study drug\n\n          -  Related to allergies:\n\n               -  Known allergy to components of the study drug (microcrystalline cellulose,\n                  mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium\n                  dioxide, polyethylene glycol and talc)\n\n               -  Documented history of acute (anaphylaxis) or delayed (Stevens-Johnson syndrome\n                  or epidermal necrolysis) allergy to sulfa drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135614", 
            "org_study_id": "GS-US-218-1227"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-5806", 
                "description": "GS-5806 200 mg (4 x 50 mg tablets) administered orally", 
                "intervention_name": "GS-5806", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to match GS-5806", 
                "description": "Placebo to match GS-5806 administered orally", 
                "intervention_name": "Placebo to match GS-5806", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Lambton", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "John Hunter Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "Westmead Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nambour", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "Nambour Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Redcliffe", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "Redcliffe Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southport", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "Gold Coast Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Monash Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankston", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Frankston Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tauranga", 
                        "country": "New Zealand", 
                        "state": "Bay of Plenty"
                    }, 
                    "name": "Tauranga Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "state": "North Island"
                    }, 
                    "name": "Greenlane Clinical Centre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "state": "South Island"
                    }, 
                    "name": "Canterbury Respiratory Services"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection", 
        "overall_contact": {
            "email": "erin.naylor@gilead.com", 
            "last_name": "Erin Leigh Naylor", 
            "phone": "1 206 832 2083"
        }, 
        "overall_contact_backup": {
            "email": "Sheila.leitzinger@gilead.com", 
            "last_name": "Sheila Leitziner", 
            "phone": "1 206 256 4904"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Jason Chien, MD, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Canada: Health Canada", 
                "New Zealand: Medsafe"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Daily average change in log10 viral load from Day 1 to Day 5.", 
            "measure": "Daily average change in respiratory syncytial viral load", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135614"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The FLU-PRO is a patient-reported outcome questionnaire utilized as a standardized method for evaluating symptoms of influenza.", 
                "measure": "Daily average change in the FLU-PRO score", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 5"
            }, 
            {
                "measure": "Duration of hospital stay following GS-5806 administration", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "description": "Rate of unplanned medical encounters (clinic visits, emergency room visits, urgent care visits, and rehospitalizations) related to a respiratory illness after initial hospital discharge through Day 28", 
                "measure": "Rate of unplanned medical encounters", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}